OPP-EBV-CAD Regimen as Salvage Treatment in Advanced Refractory or Resistant Multiple Myeloma

References

• Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76: 1860–6
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos MA, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83: 512–6
   PubMed Web of Science ®Google Scholar
• Durie BGM, Salmon SE. Clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–54
   PubMed Web of Science ®Google Scholar
• Durie BMG. Staging and kinetics of multiple myeloma. Sem Oncol 1986; 13: 300–9
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstaten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–12
   PubMed Web of Science ®Google Scholar
• Chronic Leukemia-Myeloma Task Force. Proposed guide-lines for protocol studies: II. Plasma cell myeloma. Cancer Chemotherapy Reports 1973; 4: 145–57
   Google Scholar
• Cavo M, Benni M, Gozzetti A, Tura S. The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. Bailliere's Clin Haematol 1995; 8, (4) 795-813
   PubMed Web of Science ®Google Scholar
• Joshua DE, Gibson J, Brown RD. Mechanism of the escape phase of myeloma. Blood Rev 1994; 8: 13–20
   PubMed Web of Science ®Google Scholar
• Kraut EH, Crowley JJ, Wade JL, Laufman LR, Alsina M, Taylor SA, Salmon SE. Evaluation of topotecan in resistant and relapsing multiple myeloma: a South West Oncology Group study. J Clin Oncol 1998; 16: 589–92
   PubMed Web of Science ®Google Scholar
• Case DC, Lee BJ, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 1977; 63: 897–03
   PubMed Web of Science ®Google Scholar
• Cavo M, Galieni P, Tassi C, Gobbi M, Tura S. M-2 protocol for melphalan-resistant and relapsing multiple myeloma. Eur J Haematol 1988; 4: 168–73
   Google Scholar
• Paccagnella A, Cartei G, Fosser V, Salvagno L, Bolzonella S, Chiarion Sileni VC, Fiorentino MV. Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. Eur J Cancer and Clin Oncol 1983; 19: 1345–51
   PubMedGoogle Scholar
• Bonnet J, Alexanian R, Salmon SE, Bottemley R, Amare M, Haut A, Dixon D. Vincristine, BCNU, doxorubicin and prednisolone (VBAP) combination in the treatment of relapsing or resistant myeloma: a South West Oncology Group study. Cancer Treat Rep 1982; 66: 1267–71
   PubMedGoogle Scholar
• Kyle RA, Pajak TF, Henderson ES, Nawabi IV, Brunner K, Henry PH, McLntyre OR, Holland JF. Multple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, BCNU and prednisone. Cancer Treat Rep 1982; 66: 451–5
   PubMedGoogle Scholar
• Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–6
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Int Med 1986; 105: 8–11
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos MA. Management of multiple myeloma. Semin Hematol 1995; 32: 20–30
   PubMed Web of Science ®Google Scholar
• Anderson H, Scarffe JH, Lambert M, Smith DB, Chan CC, Chadwick G, McMahon A, Chang J, Crowther D, Swindell R. VAD chemotherapy toxicity and efficacy in patients with multiple myeloma and other lymphoid malignacies. Hematol oncol 1987; 5: 213–22
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Meuwissen Ojath Bast EJEG, Dekker W. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989; 71: 25–30
   PubMed Web of Science ®Google Scholar
• Browman PG, Belch A, Skillings J, Wilson K, Bergsagel D, Johnston D, Pater JL. Modified adriamycin-vincristine-dex-amethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. Br J Haematol 1992; 82: 555–9
   PubMed Web of Science ®Google Scholar
• Forgeson GV, Selby P, Lakhani S, Zulian G, Viner C, Mait-Land J, McElwain TJ. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously-treated multiple myeloma patients. Br J Cancer 1988; 58: 469–73
   PubMed Web of Science ®Google Scholar
• Lenhard Re Oken MM, Barnes JM, Humphrey RL, Glick JH, Silverstein MN. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 1984; 53: 1456–60
   PubMed Web of Science ®Google Scholar
• Barlogie B, Velasquez WS, Alexanian R, Cabanillas F. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol 1989; 7: 1514–7
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Dixon DO, Purvis JD, Bonnem E, Alexanian R. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 1990; 76: 677–80
   PubMed Web of Science ®Google Scholar
• Gimsing P, Bjerrum OW, Brandt E, Ellegaard J, Evensen SA, Hansen MM, Hedenus M, Hippe E, Keldsen N, Palva I, Rod-Jer S, Talstad I, Westin J, Wisurff F. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP regimen) a phase II study. Br J Haematol 1991; 77: 73–9
   PubMed Web of Science ®Google Scholar
• Leoni F, Ciolli S, Caporale R, Salti F, Rossi Ferrini PL. Continuous infusion cyclophosphamide in combination with teniposide and dexamethasone in refractory myeloma. Leukemia Lymphoma 1992; 7: 481–7
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Delasalle KB, Champlin R, Alexanian R. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haematol 1993; 83: 240–4
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 1996; 52: 77–81
   PubMed Web of Science ®Google Scholar
• Celesti L, Clavio M, Poggi A, Casciaro S, Vallebella E, Gobbi M. The association of cyclophosphamide and dexamethasone in advanced refractoy multiple myeloma patients. Haematologica 1997; 82: 351–3
   PubMedGoogle Scholar
• Fossa A, Muer M, Kasper C, Welt A, Seeber S, Nowrousian MR. Bolus vincristine and epirubicin wih cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Leukemia 1998; 12: 422–6
   PubMed Web of Science ®Google Scholar
• Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M, Monto R, Wilson H. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382–9
   PubMed Web of Science ®Google Scholar
• Palmer M, Belch A, Brox L, Pollock E, Koch M. Are current criteria for response useful in the management of multiple myeloma?. J Clin Oncol 1987; 5: 1373–7
   PubMed Web of Science ®Google Scholar
• Blade J, Lopez-Guillermo A, Bosch F, Cervantes F, Reverter J-C, Montserrat E, Rozman C. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol 1994; 88: 117–21
   PubMed Web of Science ®Google Scholar
• Baldini L, Radaelli F, Chiorboli O, Fumagalli S, Cro L, Seg-Ala M, Cesana BM, Polli EE, Maiolo AT. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. Cancer 1991; 68: 62–7
   PubMed Web of Science ®Google Scholar
• Goldie J, Coldman A. A mathematic model for relating the drug sensitivity of tumors to their spontaneous remission rate. Cancer Tret Rep 1979; 63: 1727–33
   PubMedGoogle Scholar